title: Immunohistochemical profile of breast cancer with respect to estrogen receptor and HER2 status.
abstract: There are a few studies that have evaluated a panel of stains on a single large data set of breast cancers, which is required for direct comparison between antibodies. The immunohistochemical panel in this study was chosen to include breast-specific markers and markers that are expressed in tumors resembling breast cancer. The individual marker positivity in decreasing order was 95% (177/186) for GATA-3, 92% (172/186) for cytokeratin (CK)7, 80% (151/189) for AR, 80% for estrogen receptor (158/198), 69% for progesterone receptor (137/198), 55% (105/190) for NY-BR-1, 52% (99/189) for mammaglobin, 31% (59/191) for vimentin, 26% (51/195) for GCDFP-15, 0.5% (1/186) for CK20, and 0% (0/188) for PAX-8. When tumors were categorized based on estrogen receptor and HER2 status; a total of 45 profiles were identified. In addition, some tumors showed an unconventional profile-although the majority of breast carcinomas were CK7-positive/CK20-negative, a CK7-negative/CK20-negative profile was seen in ∼8% of the cases. Such a profile can create confusion in investigation of a carcinoma of unknown origin. The results define the individual sensitivity of each marker and establish a baseline diagnostic profile of breast cancer in a large data set. In addition, the results support the use of immunohistochemical panel for confirming or determining breast as the source of metastasis.
authors.affiliation: Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA.
authors.forename: Nika C
authors.initials: NC
authors.lastname: Gloyeske
authors.forename: Anna H
authors.initials: AH
authors.lastname: Woodard
authors.forename: Esther
authors.initials: E
authors.lastname: Elishaev
authors.forename: Jing
authors.initials: J
authors.lastname: Yu
authors.forename: Beth Z
authors.initials: BZ
authors.lastname: Clark
authors.forename: David J
authors.initials: DJ
authors.lastname: Dabbs
authors.forename: Rohit
authors.initials: R
authors.lastname: Bhargava
mesh_terms: D000912:Antibodies, Neoplasm / Q000737:chemistry*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*
chemical_list: D000912:Antibodies, Neoplasm; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C508053:ERBB2 protein, human